Genmab — Februar 2019

[polle1]

bibob a lula, wait and see, snart bliver det helt anderledes

[bibob]

Ja, jeg er heller ikke nervøs, men jeg tror først vi rykker efter en god guiding. Men nervøs ! ikke tale om

[polle1]

[peter12]

Så skal du sove 6 børsdage endnu

[StockBull]

Ser da meget godt. Lıdt posıtıv snak saa er der medvıng ıgen. TA ser ı mın lılle verden ogsaa ud som om de lange bukser saa smaat er ved at komme paa

[bibob]

Oh nooo. Bare jeg kan sove for spænding.

[StockBull]

Guıdıng naeste uge vıl kunne kıckstarte et breakout

[StockBull]

tror tıl gaengaeld guıdıng skal vaere meget daarlıg for at kursen skan under 900 ıgen

[E_L]

Transplant-Ineligible Myeloma: Daratumumab
. OncLiveTV - https://www.youtube.com/watch?v=fwbC9IUOo80

[E_L]

don't think it was posted yet?

[E_L]

• Alcyone: After receiving 9 cycles of D-VMP, then just on Dara alone for maintenance; infection risk in the first 9 cycles; after that not many side effects; great strategy in this group of elderly patients
  (-> Dara only is cheaper as well offcourse)

[E_L]

• MAIA: for the elderly it is practice changing, SC future hightly convenient. Will be on-label very soon. “February 1st it will be standard therapy for me…”

[Bulder]

In think it is recorded before ash. But nevertheless they were all excited about dara. Fonseca: Maia curves much better than SWOG. I think he is exaggerating. Better but not much better.

[Bulder]

Important though in an elderly frail population: DRd seems milder than RVd.

[JørgenVarnæs]

er der nogen, der har tallene på tisotumab respons i cervical og bladder? Jeg tænker på N for population og patienter med respons

[JørgenVarnæs]

jeg kan ikke lige se de tal fra The Lancet - men kun responsraten for de 2 indikationer

[E_L]

does escalation 2 bladder, 2 cervical (from 27)

[E_L]

dose expansion 15 bladder 34 cervical (from 147)

[E_L]

table 1 from the link at 09:57

[JørgenVarnæs]

I've tried opening your link a few times since you posted. I cannot connect